EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111878" target="_blank" >RIV/00843989:_____/25:E0111878 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603DMM

Result on the web

<a href="https://doi.org/10.1038/s41571-025-01041-x" target="_blank" >https://doi.org/10.1038/s41571-025-01041-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41571-025-01041-x" target="_blank" >10.1038/s41571-025-01041-x</a>

Result language

angličtina

Original language name

EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Original language description

Since the publication in 2021 of the European Hematology Association (EHA) Clinical Practice Guidelines for the treatment of patients with smouldering multiple myeloma (SMM) and multiple myeloma (MM), developed in collaboration with the European Society for Medical Oncology, a novel international staging system (R2-ISS) has been developed, several prognostic factors are entering clinical practice (such as minimal residual disease, circulating plasma cells and monoclonal protein assessed by mass spectrometry) and, at the time of writing, 14 novel regimens have been approved by the EMA and/or the FDA for the treatment of patients with MM. A multidisciplinary group of experts from the EHA and European Myeloma Network, based in various institutions mostly located in Europe, have updated the previous guidelines and produced algorithms for everyday clinical practice that incorporate levels of evidence and grades of recommendation based on the aforementioned new data. In these Evidence-Based Guidelines, we provide key treatment recommendations for both patients with newly diagnosed MM and those with relapsed and/or refractory MM, including guidance for the use of established drugs as well as contemporary immunotherapies. Novel approaches for the management of patients with SMM focus on those who might require early intervention. Finally, we provide recommendations for myeloma-related complications and adverse events, such as bone disease, renal impairment and infections, as well as for those associated with T cell-mobilizing therapies, such as cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Nature reviews clinical oncology

ISSN

1759-4774

e-ISSN

1759-4782

Volume of the periodical

22

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

21

Pages from-to

680-700

UT code for WoS article

001523867400001

EID of the result in the Scopus database

2-s2.0-105009886617